The growing pipeline of cell and gene therapies has led to an increase in demand for high-quality gene delivery vehicles and, therefore, has created significant opportunities for companies with expertise in manufacturing viral and non-viral vectors. In an article published last year, I discussed the growing cell and gene therapy market and how it has positively influenced the growth of the vector manufacturing market.
The current vector manufacturing landscape comprises of several players that claim to have the capability to develop vectors for cell and gene therapies. The infographic below summarizes the key facts associated with the vector contract manufacturing market.
In a recent market research report, Roots Analysis interviewed several key stakeholders in the vector manufacturing market to understand the key challenges that the industry is currently facing. The key stakeholders interviewed are:
Menzo Havenga (Chief Executive Officer and President, Batavia Biosciences)